FDA Determines Regulatory Review Period for Uroxatral Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially announced its decision on the regulatory review period for Uroxatral, a human drug product, following a patent extension application submitted to the US Department of Commerce.